How about 667%? In short: there is much, much worse. And even beyond being worse there could be some abominable reporting by the media.
Just to show how much worse: there is a company with no researchers, only admin, and two (exactly: two) compounds. Of which only one has ever been in a clinical trial. Riding a dead horse they did a trial of it in HCV with interferon somewhen in 2015 (when everyone not only knew, but saw that interferon therapy is dead). Oh, and by itself it only showed a 1 Log reduction. And if I remember correctly, the AE lead to quite some people dropping out of the study (diarrhea, but if I recall correctly even other).
As everyone on this board probably knows a little bit about HCV, please read their press statements about HCV over the years. You'd laugh or cry how retail investors have been let's say "separated from their money" to carry on with irrelevant trials and save the director's job.
P.S: absolutely no endorsement, please instead look into Gilead's laboratories for new groundbreaking compounds, I think I posted about some time ago. Though, at the current time with the CAR-T commercial risk I wouldn't hold them either.
Market Data 
Markets 
AI
